/EPIX
EPIX Stock - ESSA Pharma Inc.
Healthcare|BiotechnologyNASDAQ
$0.20-1.85%
$0.00 (-1.85%) • Oct 13
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.59
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+5531.2%upside
Target: $11.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EPIX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.20 – $0.20
TARGET (TP)$11.33
STOP LOSS$0.19
RISK/REWARD1:993.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.53
52W High$6.45
52W Low$0.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-90,681 | $-118,491 | $-121,787 | $-109,464 | $-110,324 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-34,421,017 | $-32,134,104 | $-35,342,787 | $-36,908,573 | $-23,115,324 |
| Net Income | $-28,542,821 | $-26,582,343 | $-35,103,000 | $-36,805,461 | $-23,445,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.64 | $-0.60 | $-0.80 | $-0.96 | $-1.04 |
Company Overview
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$10
Average Target
↑ 4621.7% Upside
Now
$2
Low
$10
Average
$17
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 4th 2024 | Jefferies | Downgrade | Hold | - |
| November 4th 2024 | Oppenheimer | Downgrade | Perform | - |
| November 4th 2024 | Piper Sandler | Downgrade | Neutral | $2← $15 |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $17 |
Earnings History & Surprises
EPIXBeat Rate
78%
Last 18 quarters
Avg Surprise
+17.1%
EPS vs Estimate
Beats / Misses
14/3
1 met exactly
Latest EPS
$-0.09
Q3 2025
EPS Surprise History
Q4 23
+45.5%
$-0.12vs$-0.22
Q1 24
+17.6%
$-0.14vs$-0.17
Q2 24
-5.3%
$-0.20vs$-0.19
Q3 24
+38.5%
$-0.16vs$-0.26
Q4 24
+26.3%
$-0.14vs$-0.19
Q1 25
-5.6%
$-0.19vs$-0.18
Q2 25
+26.3%
$-0.14vs$-0.19
Q3 25
+47.1%
$-0.09vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q4 2025 | Dec 16, 2025 | — | — | — | — |
Q3 2025 | Aug 13, 2025 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q4 2024 | Dec 17, 2024 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.26 | $-0.16 | +38.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q1 2024 | Feb 13, 2024 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q4 2023 | Dec 12, 2023 | $-0.22 | $-0.12 | +45.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q4 2022 | Dec 13, 2022 | $-0.28 | $-0.14 | +50.0% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.27 | $-0.20 | +25.9% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.25 | $-0.25 | 0.0% | = MET |
Q1 2022 | Feb 3, 2022 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q4 2021 | Nov 18, 2021 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.26 | $-0.21 | +19.2% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.21 | $-0.36 | -71.4% | ✗ MISS |
Latest News
ESSA Pharma Received An Amended Interim Order From The Supreme Court Of British Columbia On September 25, 2025; The Amended Interim Order Approves The Previously Announced Date For ESSA's Special Meeting Of The Holders Of Common Shares Of The Company, Optionholders And Warrantholders Of October 3, 2025
➖ NeutralBenzinga•Sep 30, 2025, 08:37 PM
ESSA Pharma cuts shareholder payout in revised Xeno deal
📉 NegativeSeeking Alpha•Sep 24, 2025, 10:35 AM
ESSA Pharma Amends Agreement With XenoTherapeutics, Shareholders To Receive $0.12 Cash And Up To $0.14 Per CVR
➖ NeutralBenzinga•Sep 24, 2025, 10:07 AM
ESSA Pharma shares are trading lower after the company announced an $80 million capital distribution was paid.
➖ NeutralBenzinga•Aug 26, 2025, 04:36 PM
ESSA Pharma shares are trading lower after the company announced an $80 million capital distribution was paid.
➖ NeutralBenzinga•Aug 25, 2025, 08:37 PM
ESSA Pharma Confirms $80M Capital Distribution Paid August 22; Shares Began Trading Ex-Dividend August 25 After Correcting Due Bill Period
➖ NeutralBenzinga•Aug 25, 2025, 08:26 PM
Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 25, 2025, 08:25 PM
Trading Halt: Halted at 9:44:41 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 25, 2025, 01:47 PM
Frequently Asked Questions about EPIX
What is EPIX's current stock price?
ESSA Pharma Inc. (EPIX) is currently trading at $0.20 per share. The stock has moved -1.85% today.
What is the analyst price target for EPIX?
The average analyst price target for EPIX is $11.33, based on 1 analyst.
What sector is ESSA Pharma Inc. in?
ESSA Pharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is EPIX's market cap?
ESSA Pharma Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does EPIX pay dividends?
No, ESSA Pharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPGN
Apexigen, Inc.
$0.39
Mkt Cap: $0.0B
BIOR
Biora Therapeutics, Inc.
$0.22
Mkt Cap: $0.0B
CHRO
Channel Therapeutics Corporation
$1.35
Mkt Cap: $0.0B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
CSCI
COSCIENS Biopharma Inc.
$2.11
Mkt Cap: $0.0B
IMVIF
IMV Inc.
$0.00
Mkt Cap: $0.0B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
SCPX
Scorpius Holdings, Inc.
$0.00
Mkt Cap: $0.0B
TNFA
TNF Pharmaceuticals, Inc.
$5.20
Mkt Cap: $0.0B
TSBX
Turnstone Biologics Corp.
$0.35
Mkt Cap: $0.0B
Explore stocks similar to EPIX for comparison